Kirk E Hevener

List of Publications by Year
in descending order

39 papers	1,687 citations	430442 18 h-index	315357 38 g-index
39 all docs	39 docs citations	39 times ranked	2872 citing authors

#	Article	IF	Citations
1	Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. Journal of Chemical Information and Modeling, 2009, 49, 444-460.	2.5	367
2	Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis. Journal of Medicinal Chemistry, 2013, 56, 6560-6572.	2.9	215
3	Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharmaceutica Sinica B, 2018, 8, 844-861.	5.7	166
4	Comparison of radii sets, entropy, <scp>QM</scp> methods, and sampling on <scp>MMâ€PBSA</scp>, <scp>MMâ€GBSA</scp>, and <scp>QM/MMâ€GBSA</scp> ligand binding energies of <scp>F</scp>. tularensis enoylâ€<scp>ACP</scp> reductase (<scp>F</scp>abI). Journal of Computational Chemistry, 2015, 36, 1859-1873.	1.5	91
5	Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2004, 47, 5276-5283.	2.9	81
6	A statistical framework to evaluate virtual screening. BMC Bioinformatics, 2009, 10, 225.	1.2	81
7	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. Journal of Medicinal Chemistry, 2010, 53, 166-177.	2.9	81
8	Structureâ€“activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 1007-1020.	1.4	61
9	Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching. Journal of Medicinal Chemistry, 2012, 55, 268-279.	2.9	57
10	The Structure of the Pantothenate KinaseÂ·ADPÂ·Pantothenate Ternary Complex Reveals the Relationship between the Binding Sites for Substrate, Allosteric Regulator, and Antimetabolites. Journal of Biological Chemistry, 2004, 279, 35622-35629.	1.6	47
11	Quantitative structureâ€“activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic and Medicinal Chemistry, 2008, 16, 8042-8053.	1.4	46
12	Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 859-867.	1.3	39
13	The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. ACS Infectious Diseases, 2019, 5, 208-217.	1.8	30
14	Hit-to-Lead: Hit Validation and Assessment. Methods in Enzymology, 2018, 610, 265-309.	0.4	23
15	High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes. PLoS ONE, 2013, 8, e75144.	1.1	21
16	Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5933-5941.	2.9	20
17	Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcones and Derivatives. ACS Omega, 2018, 3, 18343-18360.	1.6	20
18	Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	20

#	Article	IF	Citations
19	Synergistic Inhibitor Binding to the Papainâ€Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. ChemMedChem, 2013, 8, 1361-1372.	1.6	19
20	Recent advances in the rational design and optimization of antibacterial agents. MedChemComm, 2016, 7, 1694-1715.	3.5	19
21	Fragment-Based Drug Discovery Using a Multidomain, Parallel MD-MM/PBSA Screening Protocol. Journal of Chemical Information and Modeling, 2013, 53, 560-572.	2.5	18
22	Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1292-1296.	1.0	18
23	Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation. Methods in Molecular Biology, 2018, 1800, 275-285.	0.4	18
24	High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion. Protein Expression and Purification, 2013, 88, 98-106.	0.6	16
25	Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden. Antimicrobial Agents and Chemotherapy, 2016, 60, 5604-5607.	1.4	16
26	The Vacuolar Ca ²⁺ ATPase Pump Pmc1p Is Required for Candida albicans Pathogenesis. MSphere, 2019, 4, .	1.3	14
27	Structural characterization ofPorphyromonas gingivalisenoyl-ACP reductase II (FabK). Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 105-112.	0.4	11
28	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
29	DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors. Journal of Medicinal Chemistry, 2020, 63, 10855-10878.	2.9	10
30	Antibacterial kaneoheoic acids A-F from a Hawaiian fungus Fusarium sp. FM701. Phytochemistry, 2021, 181, 112545.	1.4	9
31	Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity. ACS Chemical Biology, 2019, 14, 1528-1535.	1.6	8
32	Concise Synthesis of Tunicamycinâ€...V and Discovery of a Cytostatic DPAGT1 Inhibitor. Angewandte Chemie - International Edition, 2022, 61, .	7.2	7
33	Special Challenges to the Rational Design of Antibacterial Agents. Annual Reports in Medicinal Chemistry, 2013, 48, 283-298.	0.5	6
34	The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infectious Diseases, 2021, 7, 1044-1058.	1.8	6
35	Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. Protein Expression and Purification, 2012, 85, 100-108.	0.6	5
36	Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochemical and Biophysical Research Communications, 2019, 516, 333-338.	1.0	5

#	Article	IF	Citations
37	A simplified protocol for high-yield expression and purification of bacterial topoisomerase I. Protein Expression and Purification, 2016, 124, 32-40.	0.6	2
38	Identification of Dual-Target Compounds with Antifungal and Anti-NLRP3 Inflammasome Activity. ACS Infectious Diseases, 2021, 7, 2522-2535.	1.8	2
39	Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor. Angewandte Chemie, 0, , .	1.6	2